BioSpace News Archive

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive results from the phase 3 FOCUS study.

Sera Prognostics Inc. today announced the Centers for Medicare & Medicaid Services (CMS) has set a Medicare payment rate for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® test, the company’s proprietary proteomic blood test for measuring a woman’s risk of spontaneous preterm birth to allow more timely intervention.

FSD Pharma Inc. announced today that it is sharing pre-clinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the Company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS.

Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) and medac GmbH (“medac”) announced that medac clarified with FDA details with regard to the projected NDA resubmission of treosulfan, an alkylating agent licensed from medac to Medexus, following its Type A Meeting with the U.S. Food and Drug Administration (“FDA”).

Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021 , a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to The Rockefeller University.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced it has ranked first in Boston Globe’s 2021 Top Places to Work in the “Largest Employer” category.

National Resilience, Inc. (Resilience), a technology focused manufacturing company dedicated to broadening access to complex medicines, today announced the acquisition of SwiftScale Biologics, a San Leandro, California-based company developing cell-free protein synthesis (CFPS) technology.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators, announced the appointment of Constantine Chinoporos as Chief Business Officer and a member of the Albireo Enterprise Leadership Team.